Medicor Cancer Centres was the first cancer clinic in North America to begin prescribing DCA “off label” to cancer patients (in April 2007) under the full supervision of a medical team. We consulted with the relevant regulatory bodies in Canada and have been following their guidelines and policies. We would like to thank everyone who has expressed an interest in our DCA therapy, and gave feedback and encouragement. We would also like to acknowledge and extend a special thanks to two of our patients who brought DCA to our attention. As of this update of FAQ, we have treated over 1500 patients with DCA. This is the largest number of patients treated at any one clinic in the world. Even though we are not conducting a clinical trial, the experience gained by treating this large number of patients is extraordinary, and helps us to use DCA safely and effectively. Our real-world Observational DCA patient data is available to the public. Please click the link to learn more about the safety and effectiveness of DCA.
DCA Frequently Asked Questions
For details about DCA use as a cancer therapy, please see our DCA FAQ page.
Our second DCA publication was even more exciting: “Case Report of Long Term Complete Remission of Metastatic Renal Squamous Cell Carcinoma after Palliative Radiotherapy and Adjuvant Dichloroacetate”
Our first paper on intravenous DCA as a cancer therapy:
A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases. Khan A, Marier D, Marsden E, Andrews D, Eliaz I., Altern Ther Health Med. 2014 Oct;20(S2):21-28.
Our first paper on long-term use of DCA as a cancer therapy:
Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. Khan A, Andrews D, Blackburn AC, World J Clin Cases 2016 Oct 16;4(10):336-343
Our second paper on long-term use of DCA as a cancer therapy:
Long-term stabilization of metastatic melanoma with sodium dichloroacetate. Khan A, Andrews D, Shainhouse J, Blackburn AC, World J Clin Oncol 2017 8(4):371-377